Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice

References

• Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, et al. 2005. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925–935
   PubMed Web of Science ®Google Scholar
• Adachi K, Mizoguchi K, Kawarada S, Miyoshi A, Suzuki M, Chiba S, Deki T. 2010. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci 35:503–514
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, Zwerina J, et al. 2008. Dual inhibition of c-Abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 22:2214–2222
   PubMed Web of Science ®Google Scholar
• Andrae J, Galini R, Betsholtz C. 2008. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Margaritopoulos GA, Soufla G, Symvoulakis E, Vassalou E, Lymbouridou R, Samara KD, et al. 2010. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J Recep Signal Transduct Res 30:262–269
   PubMed Web of Science ®Google Scholar
• Antoniu SA. 2012. Nintedanib (BIBF 1120) for IPF: A tomorrow therapy? Multidiscip Respir Med 7:41–51
   PubMed Web of Science ®Google Scholar
• Azuma M, Nishioka Y, Aono Y, Inayama M, Makino H, Kishi J, Shono M, et al. 2007. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176:1243–1250
   PubMed Web of Science ®Google Scholar
• Barber NA, Ganti AK. 2011. Pulmonary toxicities from targeted therapies: A review. Target Oncol 6:235–243
   PubMed Web of Science ®Google Scholar
• Bikfalvi A. 2004. Recent developments in the inhibition of angiogenesis: Examples from studies on platelet factor-4 and the VEGF/VEGFR system. Biochem Pharmacol 68:1017–1021
   PubMed Web of Science ®Google Scholar
• Bonner JC, Lindroos PM, Rice AB, Moomaw CR, Morgan DL. 1998. Induction of PDGF receptor-alpha in rat myofibroblasts during pulmonary fibrogenesis in vivo. Am J Physiol 274:72–80
   PubMedGoogle Scholar
• Bonner JC. 2004. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255–273
   PubMed Web of Science ®Google Scholar
• Bonner JC. 2010. Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair 3:15–51
   PubMedGoogle Scholar
• Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. 2007. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29:976–985
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. 2004. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. 2010. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181:604–610
   PubMed Web of Science ®Google Scholar
• Donovan J, Shiwen X, Norman J, Abraham D. 2013. Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 6:10
   PubMedGoogle Scholar
• Galuppo M, Esposito E, Mazzon E, Di Paola R, Paterniti I, Impellizzeri D, Cuzzocrea S. 2011. MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn Schmiedebergs Arch Pharmacol 384:21–37
   PubMed Web of Science ®Google Scholar
• Haubeiss S, Schmid JO, Murdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE. 2010. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer 9:168–183
   PubMed Web of Science ®Google Scholar
• Hubner RH, Gitter W, Mokhtari NE, Mathiak M, Both M, Bolte H, Freitag-Wolf S, Bewig B. 2008. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44:507–511
   PubMed Web of Science ®Google Scholar
• Hu M, Che P, Han X, Cai GQ, Liu G, Antony V, Luckhardt T, et al. 2014. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther 351:87–95
   PubMed Web of Science ®Google Scholar
• Hu Y, Peng J, Feng D, Chu L, Li X, Jin Z, Lin Z, Zeng Q. 2006. Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta1-induced alpha smooth muscle actin expression in human fetal lung fibroblasts in vitro. Lung 184:33–42
   PubMed Web of Science ®Google Scholar
• Ishii Y, Fujimoto S, Fukuda T. 2006. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 174:550–556
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ. 2005. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11:6924–6932
   PubMed Web of Science ®Google Scholar
• Kayalar O, Oztay F. 2014. Retinoic acid induced repair in the lung of adult hyperoxic mice, reducing transforming growth factor-β1 (TGF-β1) mediated abnormal alterations. Acta Histochem 116:810–819
   PubMed Web of Science ®Google Scholar
• Kis K, Liu X, Hagood JS. 2011. Myofibroblast differentiation and survival in fibrotic disease. Expert Rev Mol Med 13:1–24
   Web of Science ®Google Scholar
• Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, et al. 2009. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 119:772–787
   PubMed Web of Science ®Google Scholar
• Lasky JA, Tonthat B, Liu JY, Friedman M, Brody AR. 1998. Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats. Am J Respir Crit Care Med 157:1652–1657
   PubMed Web of Science ®Google Scholar
• Lipson KE, Pang L, Huber LJ, Chen H, Tsai JM, Hirth P, Gazit A, et al. 1998. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp Ther 285:844–852
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Arai T, Mori M, Goya S, Kida H, Morishita H, Fujiwara H, et al. 2002. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 283:103–112
   PubMed Web of Science ®Google Scholar
• Montero JC, Seoane S, Ocana A, Pandiella A. 2011. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors. Clin Cancer Res 17:5546–5552
   PubMed Web of Science ®Google Scholar
• Murray LA, Argentieri RL, Farrell FX, Bracht M, Sheng H, Whitaker B, Beck H, et al. 2008. Hyper-responsiveness of IPF/UIP fibroblasts: Interplay between TGF-beta1, IL-13 and CCL2. Int J Biochem Cell Biol 40:2174–2182
   PubMed Web of Science ®Google Scholar
• Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, et al. 2009. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 9:70–79
   PubMed Web of Science ®Google Scholar
• Ovet H, Oztay F. 2014. The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing of lysyl oxidase expressions. Biol Trace Elem Res 162:189–199
   PubMed Web of Science ®Google Scholar
• Oztay F, Yilmaz O. 2015. Method of treating fibrotic diseases using dasatinib. TR201503969A2
   Google Scholar
• Oztay F, Gezginci-Oktayoglu S, Bayrak B, Yanardag R, Bolkent S. 2010. Cathepsin B inhibition improves lung injury associated to D-galactosamine/tumor necrosis factor-alpha-induced liver injury in mice. Mol Cell Biochem 333:65–72
   PubMed Web of Science ®Google Scholar
• Oztay F, Sacan O, Kayalar O, Bolkent S, Ipci Y, Kabasakal L, Sener G, Yanardag R. 2015. Chard (Beta vulgaris var. cicla) extract improved hyperglycemia-induced oxidative stress and surfactant-associated protein alterations in rat lungs. Pharm Biol 53:1639–1646
   Google Scholar
• Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. 1999. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13:2400–2411
   PubMed Web of Science ®Google Scholar
• Rice AB, Moomaw CR, Morgan DL, Bonner JC. 1999. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 155:213–221
   PubMed Web of Science ®Google Scholar
• Richeldi L, Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. 2011. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, et al. 2014. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X, Breitman ML, Schuh AC. 1995. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 376:62–66
   PubMed Web of Science ®Google Scholar
• Sirvent A, Benistant C, Roche S. 2008. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 100:617–631
   PubMed Web of Science ®Google Scholar
• Suzuki H, Aoshiba K, Yokohori N, Nagai A. 2003. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63:5054–5059
   PubMed Web of Science ®Google Scholar
• Swords R, Maralinga D, Padmanabhan S, Carew J, Giles F. 2009. Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 3:89–101
   PubMed Web of Science ®Google Scholar
• Trojanowska M. 2008. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47:2–4
   PubMed Web of Science ®Google Scholar
• Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, et al. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279:895–902
   PubMed Web of Science ®Google Scholar
• Vittal R, Horowitz JC, Moore BB, Zhang H, Martinez FJ, Toews GB, Standiford TJ, Thannickal VJ. 2005. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol 166:367–375
   PubMed Web of Science ®Google Scholar
• Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. 2007. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: Implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 321:35–44
   PubMed Web of Science ®Google Scholar
• Wang S, Wilkes MC, Leof EB, Hirschberg R. 2005. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19:1–11
   PubMed Web of Science ®Google Scholar
• Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. 2001. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98:4622–4627
   PubMed Web of Science ®Google Scholar
• White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, Hoqaboam CM, et al. 2006. Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am J Respir Crit Care Med 173:112–121
   PubMed Web of Science ®Google Scholar
• Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. 2014. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:209–220
   PubMed Web of Science ®Google Scholar
• Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210
   PubMed Web of Science ®Google Scholar
• Wynn TA. 2011. Integrating mechanisms of pulmonary fibrosis. J Exp Med 208:1339–1350
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, et al. 2005. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 288:907–913
   PubMed Web of Science ®Google Scholar
• Zhang K, Rekhter MD, Gordon D, Phan SH. 1994. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol 145:114–125
   PubMed Web of Science ®Google Scholar
• Zhu B, Ma AQ, Yang L, Dang XM. 2013. Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway. Int J Mol Sci 14:24476–24491
   PubMed Web of Science ®Google Scholar